Product Labeling Should Add "Expected" Adverse Event Section, Bristol Says
Executive Summary
Bristol-Myers Squibb is proposing the addition of an "expected" adverse events section to product labeling in order to minimize regulatory reporting of events that occur frequently in both drug and control groups, the company said in comments on FDA's AE labeling draft guidance.
You may also be interested in...
Adverse Reaction "Overview" Section Would Reduce Clarity - PhRMA Says
FDA's proposed "Overview" section for adverse reaction labeling would make labeling more confusing for prescribers, the Pharmaceutical Research & Manufacturers of America said in comments on the agency's draft guidance.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials